Bladder Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with high-risk non-muscle-invasive bladder cancer (a type of bladder cancer that has not spread deep into the bladder wall), confirmed by a camera examination of the bladder, including specific types such as high-grade T1, recurring high-grade Ta, certain larger or multiple tumours, carcinoma in situ (CIS), cancer that has not responded to BCG treatment, unusual cell types, lymphovascular involvement, or cancer affecting the prostatic urethra.
- People who are generally in good health and are able to attend follow-up appointments over a period of 2 years.
Who may not be able to join:
- People whose bladder cancer is not the urothelial carcinoma (UC) type.
- People whose cancer has grown into the muscle of the bladder wall, or who have a non-cancerous bladder condition.
- People whose tumour was not fully removed during surgery.
- People who currently have an active infection.
- People who also have urothelial carcinoma in the upper urinary tract or the prostatic urethra at the same time.
- People who have previously received systemic chemotherapy, immunotherapy, or radiotherapy.
- People who have low white blood cell or low platelet counts.
- People whose kidney function blood test (serum creatinine) is more than twice the upper limit of normal.
- People who have a urinary tract infection that cannot be controlled.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shuxiong Zeng, M.D. Ph.D, Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China
Phone: +8618930568759
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
One-year recurrence-free survival rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.